These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 6989713)

  • 21. An improved procedure for isolation of rat alpha-fetoprotein.
    Ali M; Balapure AK; Durani S; Sahib MK
    Indian J Biochem Biophys; 1981 Apr; 18(2):105-9. PubMed ID: 6171506
    [No Abstract]   [Full Text] [Related]  

  • 22. Plasminogen activators and urokinase inhibitors in the lungs of foetuses and newborns.
    Uszynska-Folejewska R
    Anaesth Resusc Intensive Ther; 1976; 4(1):41-5. PubMed ID: 970616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Urokinase inhibitors in blood serum samples from retroplacental blood].
    Uszyński M; Uszyńska-Folejewska R
    Ginekol Pol; 1975 Jul; 46(7):737-9. PubMed ID: 1150101
    [No Abstract]   [Full Text] [Related]  

  • 24. Purification and characterization of a low molecular mass cysteine proteinase inhibitor from human amniotic fluid.
    Rohrlich ST; Levy H; Rifkin DB
    Prog Clin Biol Res; 1985; 180():239-41. PubMed ID: 3875864
    [No Abstract]   [Full Text] [Related]  

  • 25. Activities of antiplasmin and antiplasminogen activator in serous middle ear effusions.
    Hamaguchi Y; Ohi M; Sakakura Y; Miyoshi Y
    Ann Otol Rhinol Laryngol; 1985; 94(3):293-6. PubMed ID: 3925865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Displacement chromatography of proteins.
    Peterson EA; Torres AR
    Methods Enzymol; 1984; 104():113-33. PubMed ID: 6201695
    [No Abstract]   [Full Text] [Related]  

  • 27. Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues.
    Jiang L; Zhao B; Xu P; Sørensen HP; Jensen JK; Christensen A; Hosseini M; Nielsen NC; Jensen KJ; Andreasen PA; Huang M
    Int J Biochem Cell Biol; 2015 May; 62():88-92. PubMed ID: 25744057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies on fibrinolytic inhibitors during pregnancy.
    Hedner U; Astedt B
    Acta Obstet Gynecol Scand; 1971; 50(1):99-103. PubMed ID: 5558602
    [No Abstract]   [Full Text] [Related]  

  • 29. Bicyclic peptide inhibitor of urokinase-type plasminogen activator: mode of action.
    Roodbeen R; Paaske B; Jiang L; Jensen JK; Christensen A; Nielsen JT; Huang M; Mulder FA; Nielsen NC; Andreasen PA; Jensen KJ
    Chembiochem; 2013 Nov; 14(16):2179-88. PubMed ID: 24115455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Irreversible inhibition and peptide mapping of urinary plasminogen activator urokinase.
    Reboud-Ravaux M; Desvages G; Chapeville F
    FEBS Lett; 1982 Apr; 140(1):58-62. PubMed ID: 7044821
    [No Abstract]   [Full Text] [Related]  

  • 31. [Insulin, C peptide and glucagon in amniotic fluid in normal and diabetic pregnancy].
    Andreani D; Fallucca F; Russo A; Maldonato A; Caccamo C; Lamalfa G; de Gado F; Pachi A
    Journ Annu Diabetol Hotel Dieu; 1979; ():93-101. PubMed ID: 502147
    [No Abstract]   [Full Text] [Related]  

  • 32. [On the inhibitors of fibrinolysis in the amniotic fluid and in the placental extracts of full term pregnancies].
    Slunský R; Adamcová M
    Z Geburtshilfe Gynakol; 1967; 167(2):224-31. PubMed ID: 5590814
    [No Abstract]   [Full Text] [Related]  

  • 33. Human articular cartilage contains an inhibitor of plasminogen activator.
    Yamada H; Stephens RW; Nakagawa T; McNicol D
    J Rheumatol; 1988 Jul; 15(7):1138-43. PubMed ID: 3139880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [On the question of activators of fibrinolysis in the amniotic fluid and in placental extracts of full-term pregnancies].
    Slunský R; Adamcová M
    Z Geburtshilfe Gynakol; 1967 Oct; 167(3):337-44. PubMed ID: 5597697
    [No Abstract]   [Full Text] [Related]  

  • 35. Bacterial growth inhibition by amniotic fluid. VI. Evidence for a zinc-peptide antibacterial system.
    Schlievert PS; Johnson W; Galask RP
    Am J Obstet Gynecol; 1976 Aug; 125(7):906-10. PubMed ID: 782249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. trans-4-(Aminomethyl)cyclohexane carboxylic acid methylamide (t-AMCHA methylamide) inhibits the physical interaction between urokinase-type plasminogen activator and stratum corneum, and accelerates the recovery of barrier function.
    Katsuta Y; Yoshida Y; Kawai E; Suetsugu M; Kohno Y; Inomata S; Kitamura K
    J Dermatol Sci; 2005 Dec; 40(3):218-20. PubMed ID: 16289989
    [No Abstract]   [Full Text] [Related]  

  • 37. The effects of inhibitors on the catalytic conversion of urokinase.
    Soberano ME; Ong EB; Johnson AJ
    Thromb Res; 1976 Dec; 9(6):675-81. PubMed ID: 1006636
    [No Abstract]   [Full Text] [Related]  

  • 38. Isolation and characterization of plasminogen activator from pig leucocytes.
    Kopitar M; Stegnar M; Accetto B; Lebez D
    Thromb Diath Haemorrh; 1974 Mar; 31(1):72-85. PubMed ID: 4545905
    [No Abstract]   [Full Text] [Related]  

  • 39. [Prenatal diagnosis of hemolytic disease of the fetus according to the data of study of the amniotic fluid].
    Savel'eva GM; Tabolin VA; Volodin NN; Efimov MS; Levantovskaia IN
    Vopr Okhr Materin Det; 1975 Aug; 20(8):10-5. PubMed ID: 809927
    [No Abstract]   [Full Text] [Related]  

  • 40. [Determination of middle molecule peptides in the blood and amniotic fluid in nephropathy of pregnancy].
    Avakian ZA; Kagramanian RG
    Lab Delo; 1988; (11):46-8. PubMed ID: 2463418
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.